Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17025280 | 0.86 | TP53 (0.43) | CNR2CYP19A1ADORA3TP53ADORA2A | |
| SCHEMBL4103108 | 0.80 | TP53 (0.44) | CNR2CYP19A1ADORA3TP53ADORA2A | |
| SCHEMBL25206891 | 0.79 | ADORA3 (0.39) | CNR1CNR2CYP19A1ADORA3TP53 | |
| SCHEMBL4101100 | 0.77 | P2RX7 (0.38) | CNR1CNR2CYP19A1TP53ALDH1A1 | |
| SCHEMBL23635091 | 0.77 | HPGD (0.59) | CNR1CNR2ADORA2A | |
| SCHEMBL4102167 | 0.76 | TP53 (0.37) | CNR1CNR2CYP19A1TP53LMNA | |
| SCHEMBL13734641 | 0.74 | ADORA3 (0.58) | ADORA3TP53ADORA2AADORA1ALDH1A1 | |
| SCHEMBL7567252 | 0.73 | CYP19A1 (0.53) | CNR1CNR2CYP19A1TP53ALDH1A1 | |
| SCHEMBL15650211 | 0.72 | ADORA3 (0.49) | ADORA3TP53ADORA2AADORA1 | |
| SCHEMBL14323257 | 0.71 | ADORA3 (0.48) | CNR2CYP19A1ADORA3TP53ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| CN-118804912-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4436961-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023097007-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097007-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | CNR1 4479/4885CNR2 4788/4885CYP19A1 2976/4885 |
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | CNR1 89/4885CNR2 136/4885CYP19A1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.